drugset / Trial / NCT00485875

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

NCT00485875

Phase 4 Completed 62 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess changes in ADHD symptoms and tolerability of medication in children and adolescents switching from a stimulant to atomoxetine.

Timeline

Start
2004-06
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified